In this issue of Clinics in Liver Disease , guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver . With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe. Contains 19 relevant, practice-oriented topics including association of MASH with metabolic-related diseases (diabetes, pre-diabetes, and obesity); algorithms for risk stratification in patients with MASH; management of MASLD: lifestyle modification; currently approved and future regimens for MASH; pediatric MASH; and more Provides in-depth clinical reviews on MASH/NASH fatty liver , offering actionable insights for clinical practice Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.